



FIG. 1



**FIG. 2**



**FIG. 3**




FIG. 4




FIG. 5



Tc-99m EC

Tc-99m EC-folate

Tc-99m EC

Tc-99m EC-folate







FIG. 6B


FIG. 6A



**FIG. 7**




2-Nitroimidazole-NH<sub>2</sub>




EC

1) EDC, Sulfo-NHS  
2) NaTcO<sub>4</sub> / SnCl<sub>2</sub>



**FIG. 8A**



**FIG. 8B**




FIG. 9







FIG. 10



**FIG. 11A**



**FIG. 11B**



**FIG. 12**



3-10-1999

EC-(2-NH)2 after adding serum 3

Date: Mar 10 1999  
Data File:

Start time: 16:02

Accum time: 00:00:50  
Plate: 1 Lane: 1

Elect Resolution: NORMAL

(Amp. Range: 0 - 2047)

Stop counts: 50000

Stop Counts Region: 0.00 to 20.00 cm

Rf Calculations: Origin: 1.50 cm

Solvent Front: 19.00 cm

Integration Parameters: Auto Integration

Peak slope: 1.0

Min width: 0.1 Min %: 2.0

Total Count Region: 0.00cm to 20.00cm

Total Counts: 53170

Total CPM: 63810

Reg. #	Start (cm)	Stop (cm)	Center (cm)	Rf	Region Counts	Region CPM	% of Tot Reg	% of Tot Cr
1	0.60	4.40	2.50	0.06	4557	5468	9.02	8.9
2	8.20	16.80	12.56	0.63	45980	55180	90.98	86.4
TOTAL					50540	60650	100.00	95.0





FIG. 13

99m Tc-EC


99m Tc-EC-NIM

99m Tc-EC

99m Tc-EC-NIM




15 MIN.



4 HOUR

FIG. 14A



**FIG. 14B**




FIG. 15A

*99m* Tc-EC-Nitroimidazole (NIM)  
(100 $\mu$ Ci/mouse, iv.)





FIG. 15B

*<sup>99m</sup>Tc-EC-Nitroimidazole (NIM)*



2 HOUR

FIG. 15C


1 HOUR

2 HOUR

30 MIN.


15 MIN.

*<sup>99m</sup>Tc-EC-Nitroimidazole (NIM)  
(100 $\mu$ Ci/mouse, iv.)*




TUMOR

15 MIN.




TUMOR

30 MIN.



TUMOR


1 HOUR



TUMOR

2 HOUR


FIG. 15D



Synthesis of EC-GAP


FIG. 16






30 MIN.

TUMOR




2 HOUR

TUMOR



15 MIN.


TUMOR



1 HOUR

TUMOR

FIG. 17




30 MIN.

TUMOR




2 HOUR

TUMOR



15 MIN.

TUMOR



1 HOUR

TUMOR

FIG. 18




FIG. 19A

$^{99m}\text{Tc}$ -EC-Annexin V  
(100  $\mu\text{Ci}$ /mouse, iv.)




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 21




FIG. 22






FIG. 23






FIG. 24



**FIG. 25**



**FIG. 26**






FIG. 27




**FIG. 28**



**FIG. 29**



**FIG. 30**



**FIG. 31**




FIG. 33






FIG. 32





**FIG. 34**



**FIG. 35**





FIG. 36


Synthetic scheme of  $^{99\text{m}}\text{Tc-EC-neomycin}$ .

**$^{99m}\text{Tc-EC}$**


**$^{99m}\text{Tc-EC-Neomycin}$**



0.5



2



4hrs



0.5



2



4hrs

Planar image of breast tumor-bearing rats after administration of  $^{99m}\text{Tc-EC}$  and  $^{99m}\text{Tc-EC-Neomycin}$  ( $100\mu\text{Ci/rat, iv.}$ ) showed that the tumor could be well visualized from 0.5-4 hours postinjection.

**FIG. 37A**

Scintigraphic image of breast tumor-bearing rats after administration of  $^{99m}\text{Tc-EC}$  and  $^{99m}\text{Tc-EC-neomycin}$  ( $100\mu\text{Ci/rat, iv.}$ ) showed that the tumor could be well visualized from 0.5-4 hours postinjection.

WOO IN JA

753717/EE63

80-12000

HONKWANG UNIV HOSP

SCINTIMAMMOGRAPHY EC-NEO

LT LAT-2H

RT LAT-2H


LT LAT-2H

RT LAT-2H

FIG. 37B

Scintimammography with  $^{99m}\text{Tc}$ -EC- neomycin (30 mCi, iv.) of a breast cancer patient. Images taken two hours post-injection.

EC



<sup>1</sup>H-NMR of EC.

FIG. 38A

Neomycin





FIG. 38B <sup>1</sup>H-NMR of neomycin.


EC-Neomycin



<sup>1</sup>H-NMR of EC-neomycin.

FIG. 38C

# EC-Neo 10mm/50mm DIII



Mass spectrometry of EC-neomycin ( $M^+$  1112.55).

FIG. 39



## UV Wavelength Scan of EC




FIG. 40A

UV wavelength scan of EC.

## UV Wavelength Scan of Neomycin




FIG. 40B

UV wavelength scan of neomycin.

## UV Wavelength Scan of EC-Neomycin




FIG. 40C

UV wavelength scan of EC-neomycin.

EC-NEOMYCIN 30mg + EC

# SUMMARY REPORT

Tc-99m

METHANOL-AMMONIUM ACETATE

Date: Feb 03 2000

Start time: 12:45

Accum time: 00:03:01

Data File:

Plate: 1 Lane: 1

Elect Resolution: NORMAL

(Amp. Range: 0 - 2047)

Rf Calculations: Origin: 0.00 cm

Solvent Front: 20.00 cm

Integration Parameters: Auto Integration

Peak slope: 1.0

Min width: 0.1

Min %: 2.0

Total Count Region: 0.00cm to 20.00cm

Total Counts: 48360

Total CPM: 16030

Reg. #	Start (cm)	Stop (cm)	Center (cm)	Rf	Region Counts	Region CPM	% of Tot Reg	% of Tot Cnt
1	6.50	14.90	10.57	0.53	45000	14920	100.00	93.05
TOTAL					45000	14920	100.00	93.05





FIG. 41 Radio-TLC analysis of <sup>99m</sup>Tc-EC-neomycin.

## Temp: 85.0°C



**FIG. 42**  
HPLC analysis of  $^{99m}\text{Tc}$ -EC-neomycin (radioactive detector).

<sup>99m</sup>Tc-EC-NEO

Column: Bio-Rad Carbohydrate, Aminex HPLX-87C, 250x4mm


Eluent: H<sub>2</sub>O

Flow Rate: 0.4ml/min

Detector: UV, 254nm

Temp: 85.0°C

RUN # 2 JAN 28. 1999 00:54:29  
START



RUN # 2 JAN 28. 1999 00:54:29


RT	AREA	TYPE	WIDTH	AREA%
2.315	9971165	SPH	.498	99.71165
5.125	392604	BY	.265	.15126
5.260	355901	VB	.132	.13712

TOTAL AREA=2.5955E+08

NO. FACTOR=1.0000E+00

<sup>18</sup>F-FDG

Column: Bio-Rad Carbohydrate,  
Aminex HPX-87C, 250x4mm  
Eluent: H<sub>2</sub>O  
Flow Rate: 0.4ml/min  
Detector: Radiochemical  
Temp: 85.0°C



AAAAA'AAI AAA' AA AAAAA'AAI AAAAA'AAI  
AREA TYPE MIN AREA  
AREA  
KUN # 1  
JUN 28 1999 15:31:29

AAAAA'AAI AAA' AA AAAAA'AAI AAAAA'AAI  
AREA TYPE MIN AREA  
AREA  
KUN # 1  
JUN 28 1999 15:31:29

AAAAA'AAI AAA' AA AAAAA'AAI AAAAA'AAI  
AREA TYPE MIN AREA  
AREA  
KUN # 1  
JUN 28 1999 15:31:29

FIG. 44 HPLC analysis of <sup>18</sup>F-FDG (radioactive detector).


<sup>18</sup>F-FDG

• DATE 1/28/99  
JAN 28. 1999 00:16:15

• CH1 SP 1.5 @  
• ATT 2 @ @  
• THRESH 7 @  
• LIST: LIST  
PEAK CAPACITY: 1244

ZERO = 0. -11.179  
ATT 2 = 3  
CH1 SP = 0.5  
NR REJ = 0  
THRESH = 7  
PR MD = 0.04

• RUN # 1 JAN 28. 1999 00:37:02  
START



RUN# 1 JAN 28. 1999 00:37:02

Column: Bio-Rad Carbohydrate,  
Aminex HPX-87C, 250x4mm

Eluent: H<sub>2</sub>O

Flow Rate: 0.4ml/min

Detector: UV, 254nm

Temp: 85.0°C

FIG. 45

HPLC analysis of <sup>18</sup>F-FDG (UV 254 nm).



# % of Drug Uptake in Lung Cancer Cell Line (A549)




FIG. 46  
In vitro cellular uptake assay of a series of  $^{99m}\text{Tc}$ -EC-drug conjugates in lung cancer cell line.  $^{99m}\text{Tc}$ -EC- neomycin showed

the highest uptake in the cells tested

# % of Drug Uptake in Human Lung Cancer Cell Line (A549)





FIG. 47  
Effect of glucose on cellular (A549) uptake of  $^{99m}\text{Tc}$ -EC- neomycin and  $^{18}\text{F}$ -FDG.

# % of Drug Uptake in Human Lung Cancer Cell Line (H1299)



Effect of glucose on cellular (H1299) uptake of  $^{99m}\text{Tc}$ -EC-

FIG. 48A

Effects of Glucose Loading on  $^{99m}\text{Tc}$ -EC-Neomycin in Human Lung Cancer Cell Line (H1299)




FIG. 48B





FIG. 49      Synthesis of  $^{99\text{m}}\text{Tc-EC-Glucosamine}$

## Hexokinase Assay of Glucose

WAVELENGTH SCAN/0

03/01/00 14:41




301.5 nm 0.889 ABS  
342.0 nm 2.044 ABS

FIG. 50

## Hexokinase Assay of Glucosamine

WAVELENGTH SCAN/0

03/01/00 14:50




301.5 nm 0.193 ABS  
341.5 nm 0.360 ABS

FIG. 51

## Hexokinase Assay of EC-Glucosamine

WAVELENGTH SCAN/0

03/01/00 14:45



302.5 nm 1.897 ABS  
341.5 nm 0.523 ABS


FIG. 52



# Hexokinase Assay of EC-GAP-Glucosamine


WAVELENGTH SCAN/0

03/01/00 15:37




302.0 nm 1.620 ABS

FIG. 53



## D(+)-Glucosamine

## EC-GAP

<sup>99m</sup>Tc-EC-GAP-Glucosamine

**FIG. 54**  
**Synthesis of  $^{99m}\text{Tc}$ -EC-GAP-Glucosamine**

In Vitro Cellular Uptake of  $^{99m}\text{Tc}$ -EC in Human Lung Cancer Cell Line (A549)




FIG. 55A

In Vitro Cellular Uptake of  $^{99m}\text{Tc}$ -EC-DG-GAP in Human Lung Cancer Cell Line (A549)




FIG. 55B

In Vitro Cellular Uptake of  $^{18}\text{F}$ FDG In Human Lung Cancer Cell Line (A549)




FIG. 55C



Tumor-to-tissue count density ratios of  $^{99m}\text{Tc}$ -EC-GAP in breast tumor-bearing rats  
(n=3/Interval; 10  $\mu\text{Ci}$ /rat, IV)




FIG. 56

In Vitro Cellular Uptake of  $^{18}\text{F}$ FDG with Glucose Loading at 2 Hours Post-Injection In Breast  
Cancer Cell Line (13762)




FIG. 57

% Uptake of  $^{99m}\text{Tc}$ -EC-Neomycin In Breast Tumor-Bearing Rats





FIG. 58







Synthetic scheme of  $^{99\text{m}}\text{Tc-EC-deoxyglucose}$ .

FIG. 59

# THE G-1000 in DIAB




Yucca coccinea, a few specimens



<sup>1</sup>H-NMR of EC-deoxyribose (EC-DG).


Glucoseamine



$^1\text{H}$ -NMR of glucosamine.

RTG. 62

(<sup>99m</sup>Tc-EC-DG, TLC)



Integrals: BABGCCAF.R01

Channel: H-3		Detector:					
Name	Start - End	RT	Height (cps)	Area (Counts)	%Total (%)	%ROI (%)	
Bkg 1	0: 00- 2: 19	1: 09	539.7				
Rgn 1	2: 19- 3: 02	2: 47	31606.2	263570.8	97.99	100.00	
Bkg 2	3: 02- 3: 27	3: 14	250.1				
1 Peak				263570.8	97.99	100.00	
Total Area = 268986.1 Counts							
Bkg Area = 89999.9 Counts							
Unallocated = 5415.3 Counts (2.01%)							

Trace Parameters: BABGCCAF.R01 H-3

Trace Display Smoothing: 0.0 s  
Trace Display Shift: 0.0 s  
Trace Display Factor: 1.000  
Channel Shift: 0.0 s  
Channel Factor: 1.000

Regions were added manually.


FIG. 63

Radio-TLC analysis of <sup>99m</sup>Tc-EC-DG.

B. Rad Aminex HPX-87C  
 Column  
 250 x 4 mm  
 .4 ml/min. H<sub>2</sub>O at 85°C  
 Radiative Scan

<sup>99m</sup>Tc-EC-deoxyglucose

- ATT 2-7 8  
 - RUN 0 5 MAR 30. 1979 15143120  
 START: not ready




RUN 0 5 MAR 30. 1979 15143120

RT	AREA TYPE	WIDTH	AREA
3.320	33350000	0V	.013 100.00000

TOTAL AREA=3.3350E+07  
 MUL FACTOR=1.0000E+00

Radiative Scan

- RUN 0 6 MAR 30. 1979 15109139  
 START



<sup>99m</sup>Tc-EC

RUN 0 6 MAR 30. 1979 15109139

RT	AREA TYPE	WIDTH	AREA
3.701	16671194	0V	.310 100.00000

TOTAL AREA=1.6671E+07

FIG. 64

HPLC analysis of <sup>99m</sup>Tc-EC-deoxyglucose and <sup>99m</sup>Tc-EC-  
 (radioactive detector).

• ATT 2- BREAK


• BREAK

• LIST: ATT 2- = 7

• ATT 2- 8 8

• RUN 1 7 MAR 30, 1999 15132137

START



Radioactive Scan

Mixed Tc-99m  
EC-Deoxy-Glucose  
EC

<sup>99m</sup>Tc-EC-deoxyglucose + <sup>99m</sup>Tc-EC  
(mixed)

FIG. 65

HPLC analysis of <sup>99m</sup>Tc-EC-deoxyglucose and <sup>99m</sup>Tc-EC  
(radioactive detector, mixed).

RUN# 7 MAR 30, 1999 15132137


AREA#	RT	AREA	TYPE	WIDTH	AREA#
	3.355	22173768	BV	.448	58.46186
	3.918	21767872	VV	.387	49.53814

TOTAL AREA=4.3942E+07  
MUL FACTOR=1.0000E+00

# Hexokinase Assay of Glucose

WAVELENGTH SCAN/0

03/01/00 14:41



301.5 nm 0.889 ABS  
342.0 nm 2.044 ABS

FIG. 66


Hexokinase assay of glucose.



## Hexokinase Assay of FDG

WAVELENGTH SCAN/0

03/09/00 14:34



340.0 nm 1.906 ABS  
346.5 nm 1.351 ABS


FIG. 67

Hexokinase assay of FDG.

# Hexokinase Assay of EC-Glucosamine (EC-DG)

WAVELENGTH SCAN/0

03/01/00 14:45



302.5 nm 1.897 ABS  
341.5 nm 0.523 ABS


FIG. 68 Hexokinase assay of EC-DG.

# % of Drug Uptake in Lung Cancer Cell Line (A549)




**FIG. 69** In vitro cellular uptake assay of  $^{99m}\text{Tc}$ -EC-deoxyglucose,  $^{99m}\text{Tc}$ -EC and  $^{18}\text{F}$ -FDG in lung cancer cell line (A549).  $^{99m}\text{Tc}$ -EC-DG showed similar uptake compared to  $^{18}\text{F}$ -FDG.

***In Vitro* Cellular Uptake of  $^{99m}\text{Tc}$ -EC-DG in Breast Cancer Cells after Glucose Loading (2 hours incubation; 2uCi/well; 50,000 cells/well; 0.5mL/well)**




**FIG. 70**  
Effect of d- and l-glucose on breast cellular (13762 cell line) uptake of  $^{99m}\text{Tc}$ -EC-DG.

*In Vitro* Cellular Uptake of  $^{18}\text{F}$  FDG in Breast Cancer Cells after Glucose Loading (2 hours incubation; 2uCi/well; 50,000 cells/well; 5mL/well)




**FIG. 71** Effect of d- and l-glucose on breast cellular (13762 cell line) uptake of  $^{18}\text{F}$ -FDG.

*In Vitro* Cellular Uptake of  $^{18}\text{F}$ FDG in Lung Cancer Cells after Glucose Loading (2 hours incubation;  
2 $\mu\text{Ci}$ /well; 50,000 cells/well; 5mL/well)



**FIG. 72** Effect of d- and l-glucose on lungcellular (A549 cell line) uptake of  $^{18}\text{F}$ FDG.

*In Vitro* Cellular Uptake of  $^{99m}\text{Tc-EC-DG}$  in Lung Cancer Cells after Glucose Loading (2 hours  
incubation;  $2\mu\text{Ci/well}$ ; 50,000 cells/well;  $0.5\text{mL/well}$ )



**FIG. 73** Effect of d- and l-glucose on breast cellular (A549 cell line) uptake of  $^{99m}\text{Tc-EC-DG}$ .

# Effect of Intravenous Injection of Glucosamine and EC-DG on Blood Glucose Level in Rats





FIG. 74  
Effect of *in vivo* blood glucose level induced by glucosamine and  
EC-DG (1.2 mmol/kg, i.v.).




# Effect of Intravenous Injection of FDG and FDG+Insulin on Blood Glucose Level in Rats




**FIG. 75** Effect of *in vivo* blood glucose level induced by FDG (1.2 and 1.9 mmol/kg, i.v.) and insulin.

# Tumor-to-Tissue Count Density Ratios of $^{99m}\text{Tc-EC-Deoxyglucose}$ in Breast Tumor-Bearing Rats




**FIG. 76** Tumor-to-tissue count density ratios of  $^{99m}\text{Tc-EC-deoxyglucose}$  in breast tumor-bearing rats.

# *In Vivo Uptake of $^{99m}\text{Tc}$ -EC-Deoxyglucose in Breast Tumor-Bearing Rats*




**FIG. 77** In vivo biodistribution of  $^{99m}\text{Tc}$ -EC-deoxyglucose in breast tumor-bearing rats.

# *In Vivo* Uptake of $^{99m}\text{Tc}$ -EC-Deoxyglucose in Lung Tumor-Bearing Nude Mice




**FIG. 78** In vivo tissue uptake of  $^{99m}\text{Tc}$ -EC-deoxyglucose in lung tumor-bearing mice.

# *In Vivo* Uptake of $^{99m}\text{Tc}$ -EC-Neomycin in Lung Tumor-Bearing Nude Mice



**FIG. 79** In vivo tissue uptake of  $^{99m}\text{Tc}$ -EC-neomycin in lung tumor-bearing mice.


# *In Vivo* Uptake of $^{18}\text{F}$ FDG in Lung Tumor-Bearing Nude Mice



**FIG. 80** In vivo tissue uptake of  $^{18}\text{F}$ FDG in lung tumor-bearing mice.

$^{99m}\text{Tc-EC}$

$^{99m}\text{Tc-EC-Glucose(6)}$



0.5




2



4hrs



0.5



2



4hrs

Planar image of breast tumor-bearing rats after administration of  $^{99m}\text{Tc-EC}$  and  $^{99m}\text{Tc-EC-Glucose(6)}$  ( $100\mu\text{Ci/rat, iv.}$ ) showed that the tumor could be well visualized from 0.5-4 hours postinjection.

FIG. 81 Planar image of breast tumor-bearing rats after administration of  $^{99m}\text{Tc-EC}$  and  $^{99m}\text{Tc-EC-deoxyglucose}$  ( $100\mu\text{Ci/rat, iv.}$ ) showed that the tumor could be well visualized from 0.5-4 hours

Case 11/42

Dx : anaplastic astrocytoma



Pre OP



Post OP



NA YOUNG SOON

697800 F42

03A-0000 WONKWANG UNIV HOSP

99mTc EC DG 1.5H

INFERIOR->SUPERIOR


EC--DG Scan

POD-25D



99mTc EC DG 1.5H patient with aortic aneurysm

CASE 2, 1/7/61

Dx: anaplastic astrocytoma with hemorrhage



Pre -OP




Post-OP



FIG. 83A MRI of a patient with hemorrhagic astrocytoma.

SEO JOK RY 799085 FRI 05 Apr 2010 WONKWANG UNIV HOSP



LC-DG Scan POD-26D

FIG. 83B SPECT with  $^{99m}\text{Tc}$ -EC-DG of a patient with astrocytoma.

Case 5 : M/62

Dx : Meningioma




FIG. 84A MRI of a patient with benign meningioma.

12

11

10



16

15

10

3

20

19

18

2

24

3

52

3

INFERIOR -> SUPERIOR:

99mTc-FC-DC-1.5H

**SPECT with  $^{99m}\text{Tc}$ -EC-DG of a patient with benign meningioma**

**FIG. 84B**

Case 4. M/11

Dx: Pul. nodule (only necrotic material on biopsy)

TB pleurisy




FIG. 85A CT of a patient with TB in lung.




FIG. 85B

SPECT with  $^{99m}\text{Tc}$ -EC-DG of a patient with TB showed no focal



Case 5 : 59/M

Dx: Squamous carcinoma




Pre RTX



Post RTX



Pre RTX



Post RTX



JUNG KI WOON  
EC DG 1H

758434 M59

10Apr2000

WONKWANG UNIV HOSP




F



L



L



F

ANT

LUNG CANCER POST RTX 1WK

ANT

POST

EC 1H


FIG. 86B

Whole body images of  $^{99m}\text{Tc}$ -EC-DG of a patient with lung cancer

JUN 11 1982 NOON

7584321459

10 APR 1980 WONKWANG UNIV HOSP



INFERIOR->SUPERIOR



EC DG 1H 30 MIN LUNG CANCER POST RTX 1WK

FIG. 86C

SPECT with  $^{99m}\text{Tc}$ -EC-DG of a patient with lung cancer, the tumor showed focal intensified uptake.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**